A "Me Too" FDA Breakthrough

By Dave Williamson – May 8, 2013 at 10:40AM

NYSE: ABBV

AbbVie

Market Cap

$283B

Today's Change

(-4.58%) -$7.67

Current Price

$159.62

Price as of April 26, 2024, 4:00 p.m. ET

Why AbbVie's Food and Drug Administration breakthrough designation isn't a big deal.

AbbVie recently received the Food and Drug Administration's new breakthrough designation for its interferon-free hepatitis C treatment regimen. Although the product is groundbreaking and likely a future blockbuster, Motley Fool health care analyst David Williamson cautions investors not to get too excited over this development.

Watch the video below and find out why despite the new breakthrough status, AbbVie may have trouble competing.

Follow David on Twitter: @MotleyDavid.

David Williamson has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences and Vertex Pharmaceuticals. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.